文献速递淋巴瘤

丹麦霍奇金淋巴瘤年轻幸存者生育率及辅助生殖技术使用情况

Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study.
PubMed 文献 · J Clin Oncol · 2021-06-25

该丹麦全国性队列纳入2000-2015年确诊、18-40岁且一线治疗后缓解的793例霍奇金淋巴瘤幸存者,按年龄、性别和生育状态匹配3965名普通人群。中位随访8.7年,幸存者生育率与匹配对照总体相似,但男性BEACOPP方案者生育率较低,幸存者更多使用辅助生殖技术。

要点

  • 霍奇金淋巴瘤幸存者总体生育率与普通人群相似。
  • 男性接受BEACOPP方案者生育率低于匹配对照。
  • 幸存者首次活产前使用辅助生殖技术比例高于对照。

核心结论

  • 未复发霍奇金淋巴瘤幸存者的生育率总体与普通人群相似。
  • 幸存者在首次活产前使用辅助生殖技术更常见,应纳入生育力保护讨论。

研究设计与样本

  • 丹麦全国性人群队列,纳入2000-2015年确诊、18-40岁且一线治疗后缓解的793例霍奇金淋巴瘤幸存者,匹配3965名普通人群对照。
  • 中位随访8.7年,使用全国出生与患者登记数据库捕获生育结局和辅助生殖技术使用。

主要发现

  • 幸存者与匹配对照在胎龄、Apgar评分或新生儿测量方面无差异。

关键数值与推荐

  • 生育率定义为霍奇金淋巴瘤诊断后9个月起每1000人年首次活产率。

临床怎么用

  • 咨询时应告知幸存者总体生育率与普通人群相似,但辅助生殖技术使用更常见。
  • 男性接受BEACOPP方案者需重点关注生育力保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The majority of young adults with Hodgkin lymphoma (HL) are cured, but chemotherapy-induced infertility can have profound psychosocial consequences. Providing data on parenthood rates and use of assisted reproductive techniques (ARTs) after contemporary HL treatment is important for patient counseling and survivorship care. MATERIALS AND METHODS: All Danish patients with HL diagnosed during 2000-2015 at the ages 18-40 years who achieved remission after first-line therapy were included and matched on age, sex, and parenthood status to five random persons from the general population. Parenthood rates were defined as the rate of first live birth per 1,000 person years, starting 9 months after HL diagnosis. Nationwide birth and patient registers were used to capture parenthood outcomes and ARTs use. RESULTS: A total of 793 HL survivors and 3,965 comparators were included (median follow-up 8.7 years). Similar parenthood rates were observed for male and female HL survivors when compared with matched comparators (56.2 v 57.1; P = .871 for males and 63.8 v 61.2; P = .672 for females). For male HL survivors, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) therapy was associated with lower parenthood rates as compared to the matched comparators (28.1 v 60.8; P = .020). Live birth after ARTs were more common for HL survivors than for comparators (males 21.6% v 6.3%; P < .001; females 13.6% v 5.5%; P = .001). There were no differences in gestational age, Apgar score, or newborn measurements between HL survivors and matched comparators. CONCLUSION: The parenthood rates for HL survivors who have not experienced relapse were generally similar to the general population. However, ARTs were used more often before the first live birth in HL survivors, which is relevant information when discussing possible long-term side effects and fertility-preserving treatment options.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Øvlisen AK, Jakobsen LH, Eloranta S, et al. Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. J Clin Oncol. 2021. PMID: 34170749. doi:10.1200/JCO.21.00357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。